Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trialComparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus diseaseHaemostatic drugs for traumatic brain injuryComparison of routes for achieving parenteral access with a focus on the management of patients with Ebola Virus DiseaseTreatment for primary postpartum haemorrhageAntifibrinolytic drugs for acute traumatic injury.Haemostatic drugs for traumatic brain injuryAntifibrinolytic drugs for acute traumatic injuryComparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic reviewAntifibrinolytic agents in traumatic haemorrhageEffects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trialEffects of tranexamic acid on platelet function and thrombin generation (ETAPlaT): WOMAN trial sub-studyThe effect of tranexamic acid on the risk of death and hysterectomy in women with post-partum haemorrhage: statistical analysis plan for the WOMAN trialEffect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trialCentral and statistical data monitoring in the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial.Use of the Oxford Handicap Scale at hospital discharge to predict Glasgow Outcome Scale at 6 months in patients with traumatic brain injuryPatient outcome after traumatic brain injury in high-, middle- and low-income countries: analysis of data on 8927 patients in 46 countries.Anti-fibrinolytic agents in post partum haemorrhage: a systematic review.Statistical analysis plan for the WOMAN-ETAPlaT study: Effect of tranexamic acid on platelet function and thrombin generation.The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trialA nested mechanistic sub-study into the effect of tranexamic acid versus placebo on intracranial haemorrhage and cerebral ischaemia in isolated traumatic brain injury: study protocol for a randomised controlled trial (CRASH-3 Trial Intracranial BleePrognostic value of major extracranial injury in traumatic brain injury: an individual patient data meta-analysis in 39,274 patients.Managing clinical trials.Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial.Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial.Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.European society of intensive care medicine study of therapeutic hypothermia (32-35 °C) for intracranial pressure reduction after traumatic brain injury (the Eurotherm3235Trial).HALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial.Using a business model approach and marketing techniques for recruitment to clinical trialsPredicting early death in patients with traumatic bleeding: development and validation of prognostic model.CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trialMarketing and clinical trials: a case study.Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients.Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms.Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): protocol and statistical analysis plan for a randomized controlled trial.Guide to the design and review of emergency research when it is proposed that consent and consultation be waived.Does tranexamic acid improve outcomes in traumatic brain injury?The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.A promise to save 100,000 trauma patients.The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.
P50
Q21560835-2C011B0B-000A-49D6-BA8F-8E169AEB3BB5Q24187946-116E84B5-C869-4D82-A3E0-60D11299B3C0Q24188122-E2667192-21A4-4A7D-92FC-F4D9995BE0BEQ24188251-9F3BF6C6-C02E-47E6-9A02-3A03E34CEA0DQ24200400-D785BE69-1678-474E-BFC0-6D9E6EB64EB9Q24202390-6FD0A2F1-C0C1-41B4-8B7E-E50DFD167F18Q24240304-6B11D104-3B18-4BFE-9C6F-6D0F85BB7A99Q24246184-EAF84832-5AB8-4293-89DE-C21A2152FE7CQ24598679-7CF1FA95-5E6E-482A-BE95-8644A951ECCAQ24805335-3BF56CD5-5E17-4849-A507-98D6870A1DF9Q28285511-73609E5D-C77A-41A1-8ECE-550CAFD79709Q28564007-3C150640-B7EF-46B1-B6F6-A0E366A34731Q28602669-5774A96D-65ED-4A76-B691-A7EFE2E2105FQ28727918-67950AE0-0A7B-4D6C-AA00-08C92394F103Q30717253-ECDEBE43-C8DC-444C-9DDC-94A1F77E8A58Q30850585-683B416E-6BB0-4C4E-BAC9-29A62F95C64BQ33368354-FFD329EE-19C4-4C10-A4BD-31D8BF3C8699Q33482473-826760E4-2B28-459A-9C0C-BD45F34AEB4CQ33562228-4F362434-3375-4CBB-A9AF-B9CAB00B9F4BQ33828581-A3CC5626-A7BA-4574-A1F9-7C9D68B14B68Q33909468-B011C0EC-CBE3-4D48-A27C-6EBF8ECD428DQ34014416-6AE81E69-713B-4B84-82D0-6FB2628A3E87Q34049734-F852A209-0B7D-4EFD-8786-7623260F6A1CQ34180460-C6022A8A-97E4-408B-B3EE-9C80F49EE0E4Q34357456-2D4D8AD8-3580-4FA7-9449-799CC39BE3A4Q34423866-E8091A9C-8E02-408B-8FE7-F81E95693A40Q34521957-5F60F74C-3FE0-47ED-A3C7-5A16AF31B2DCQ34620403-F8785B49-B4BC-435C-A068-EE512E98B6A0Q34712827-6AED7232-852B-400B-95C8-572A19175A1FQ36165273-E2B3A4C9-C452-414A-99F3-07935F559C8BQ36347953-A4B9F356-B562-42F3-B71A-3C7827B15B81Q36402162-DE628559-B091-428B-A19A-FD58473A533FQ36473793-B7AF3905-6A3C-47C5-8C72-0F3A32B9C26FQ37615859-F3DD4F0C-BE8A-43B0-9F05-92B5D2E4E148Q37701930-113171A5-7B10-4B02-BBC3-7BF55A429ACCQ38235923-1573BFB7-4B92-4DB5-A5EF-5FB4E466F5B5Q39204545-527E090D-BB78-4BDE-BF56-D10B6B5276A0Q39401875-C0D09F52-BC08-4762-85E2-522B9BED7EB5Q39450565-BD490265-8C59-4DB3-980B-8359872CAF53Q39450580-992EEAE0-4FA7-470B-9292-DE9DB7BC51C4
P50
description
Professor of Global Health Cli ...... edicine's Clinical Trials Unit
@en
wetenschapper
@nl
հետազոտող
@hy
name
Haleema Shakur-Still
@ast
Haleema Shakur-Still
@en
Haleema Shakur-Still
@es
Haleema Shakur-Still
@nl
type
label
Haleema Shakur-Still
@ast
Haleema Shakur-Still
@en
Haleema Shakur-Still
@es
Haleema Shakur-Still
@nl
prefLabel
Haleema Shakur-Still
@ast
Haleema Shakur-Still
@en
Haleema Shakur-Still
@es
Haleema Shakur-Still
@nl
P214
P244
P106
P21
P214
P244
nb2013017436
P31
P496
0000-0002-6511-109X
P7859
lccn-nb2013017436